AbbVie's diversified portfolio, including drugs from the 2019 Allergan acquisition, continues to mitigate revenue declines from Humira's patent expiration. Risks include Medicare pricing changes ...

US drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew of multibillion dollar takeovers in the biopharma sector this year. AbbVie is stumping up more ...

The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). After a thorough review of the options trading surrounding AbbVie, we move to examine the ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AbbVie ABBV in the ... The 2020 acquisition of Allergan added several new products and ...

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, AbbVie will lead development ...

AbbVie is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of its May 2025 meeting, fostering investor attention. Despite reporting a Q4 net ...

Berenberg raised the firm’s price target on AbbVie (ABBV) to $195 from $165 and keeps a Hold rating on the shares. The firm increased estimates to reflect higher immunology sales after reviewing ...

AbbVie’s immunology blockbusters Rinvoq and Skyrizi took the first and second slots, respectively, for the month, resuming the custom they upheld throughout most of 2024. Those gains over ...

AbbVie’s Allergan Aesthetics division has a presence in targeted fat reduction with CoolSculpting, a nonsurgical medical device. The company does not market this offering as a treatment for ...

The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). Financial Milestones: AbbVie's Journey Market Capitalization Analysis: With an elevated ...